Paper Details

  1. Home
  2. Paper Details

The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).

Author: KlotzU

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Mesalazine (5-ASA) is a widely used treatment for ulcerative colitis (UC) and Crohn's disease. Its modified drug delivery systems ensure targeted release at the site of inflammation, minimizing systemic exposure and side effects. 5-ASA is effective in treating mild-to-moderate UC, managing remission, and preventing postsurgical relapse. It also shows potential for chemoprevention of colorectal cancer, diverticular disease, and irritable bowel syndrome.
Paper Details　
Original Abstract of the Article :
For more than 30 years mesalazine (5-aminosalicylic acid; 5-ASA) has been used for the treatment of chronic inflammatory bowel disease (IBD) especially in ulcerative colitis (UC). During this time various rectal and oral formulations have been developed. The modified drug delivery systems were desig...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-0031-1299685

データ提供：米国国立医学図書館（NLM）

Mesalazine: A Versatile Drug for Inflammatory Bowel Disease

Mesalazine, a drug commonly used to treat inflammatory bowel disease (IBD), has been a mainstay in IBD management for over three decades. This study provides a comprehensive review of mesalazine's pharmacological profile and clinical use, highlighting its effectiveness and safety in treating IBD, particularly ulcerative colitis (UC).

Mesalazine: A Targeted Approach to IBD Treatment

The study emphasizes the targeted delivery of mesalazine to the sites of inflammation in the gut. This localized action helps to minimize systemic side effects, making mesalazine a safe and effective treatment option. The study also highlights the wide range of pharmacological properties of mesalazine, contributing to its therapeutic efficacy.

A Promising Future for Mesalazine: Expanding Applications

This research underscores the versatility of mesalazine as a therapeutic agent for IBD and beyond. The study highlights its potential benefits for patients with Crohn's disease, for preventing postsurgical relapse, and for chemoprevention of colorectal cancer.

Dr. Camel's Conclusion

Just as a camel adapts to the desert's diverse landscapes, mesalazine has proven its versatility in managing the complex terrain of IBD. This research provides a comprehensive overview of mesalazine's pharmacological profile and clinical use, highlighting its effectiveness and safety in treating IBD.

Date :
  1. Date Completed 2012-04-20
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

22344548

DOI: Digital Object Identifier

10.1055/s-0031-1299685

Related Literature

Article Analysis
・Side Effects of mesalamine rectal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.